Figure 5
The expression of EBF3 was downregulated in patients with pediatric AML. (A) Real-time PCR analysis of the transcript levels of EBF3 in 105 pediatric AML samples and 30 NBM control samples. (B) Quantification shows that EBF3 expression was found to be robustly decreased in the AML samples compared with the control samples (26.91 ± 50.86 vs. 121.14 ± 95.11, respectively; P <0.001). Those with methylated EBF3 showed significantly lower levels of EBF3 expression compared with unmethylated EBF3 (16.32 ± 12.93 vs. 34.86 ± 65.46, respectively; P = 0.043). (C) The prognostic significance of EBF3 expression was assessed in 105 Chinese pediatric AML patients with clinical follow-up records. Kaplan-Meier survival analysis revealed similar survival outcomes in tumors with high or low EBF3 expression among 105 pediatric AML patients (P = 0.091). (D) Samples with EBF3 promoter methylation revealed similar survival outcomes through Kaplan-Meier survival analysis (P = 0.190).